NCT03397329 - Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

November 13, 2017

Study Completion Date

November 13, 2017

Conditions

Healthy Volunteers

Interventions

DRUG

AG-348 Sequence A

"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)"

DRUG

AG-348 Sequence B

"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)"

Trial Locations (1)

75247

Covance Clinical Research Unit, Inc., Dallas